Fusion Genomics Receives $1 Million Award to Evaluate Novel Genomic Diagnostics Platform in Collaboration with Sunnybrook Research Institute
10 January 2020
Fusion Genomics announced that the company has been awarded $1 million to conduct a prospective clinical study evaluating its ONETest™ comprehensive, novel genomic diagnostics platform. The study is funded through the CQDM Quantum Leap program, which supports exploration of innovative technologies, tools, and platforms that accelerate or facilitate drug discovery and development. Merck is supporting the study as a member of CQDM, and Fusion Genomics will collaborate with Sunnybrook Research Institute to conduct the study.
Further reading: Business Wire
Author(s): Business Wire
Smart Innovations
Ambassador Network
Join the AMR Insights Ambassador Network today!
Connect to over 550 AMR professionals and students in 60 countries!